Celgene Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2012. For the quarter, the company reported total revenues of $1,447,410,000 compared to $1,283,897,000 a year ago. Operating income was $321,248,000 compared to $404,731,000 a year ago. Income before income taxes was $290,303,000 compared to $401,662,000 a year ago. Net income attributable to company was $263,115,000 or $0.61 per diluted share compared to $410,178,000 or $0.91 per diluted share a year ago. Adjusted net income attributable to company was $572,214,000 or $1.32 per diluted share compared to $473,058,000 or $1.05 per diluted share a year ago.

For the full year, the company reported total revenues of $5,506,713,000 compared to $4,842,070,000 a year ago. Operating income was $1,746,442,000 compared to $1,442,753,000 a year ago. Income before income taxes was $1,681,491,000 compared to $1,419,522,000 a year ago. Net income attributable to company was $1,456,180,000 or $3.30 per diluted share compared to $1,318,150,000 or $2.85 per diluted share a year ago. Adjusted net income attributable to company was $2,162,486,000 or $4.91 per diluted share compared to $1,752,908,000 or $3.79 per diluted share a year ago. Operations generated cash flow of $2,031 million for 2012, an increase of 12% compared to 2011.